Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders.

NCT05393999 is registered in ClinicalTrials.gov with Imperial College Healthcare NHS Trust as lead sponsor.

NCT NCT05393999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05393999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders.
Lead sponsor
Imperial College Healthcare NHS Trust
Phase
Phase 2
Overall status
Withdrawn
Start date
November 29, 2021
Completion date
March 4, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia, leukemia, lymphoma, myeloma, sars-cov-2 acute respiratory disease, sars-cov2 infection, thrombotic thrombocytopenic purpura (ttp)